髓源性抑制细胞与促炎因子在卵巢恶性肿瘤中的研究进展

髓源性抑制细胞（myeloid derived suppressor cells，MDSCs）是一类具有显著免疫抑制活性的异质细胞群，包括处于不同分化阶段的未成熟的粒细胞、树突状细胞和巨噬细胞等。MDSCs可抑制CD4+、CD8+ T细胞介导的适应性免疫应答，介导肿瘤免疫逃逸而促进肿瘤的生长和转移。促炎因子是一类主要由免疫细胞生成的具有许多强大生物学效应的内源性多肽，可介导多种免疫反应。MDSCs与促炎因子在卵巢癌中的分子信号传递及其机制仍不完全清楚，目前的研究提示部分促炎因子可诱导MDSCs扩增，进而促进肿瘤生长及发展。本文就MDSCs及相关促炎因子在卵巢恶性肿瘤中发生、发展和治疗的研究进行综述，以期更全面揭示MDSCs的作用机制，为探讨新的治疗方法提供理论基础。

Progress of Myeloid Derived Suppressor Cells and Proinflammatory Cytokines in Ovarian Cancer

Myeloid derived suppressor cells(MDSCs) is a kind of significant heterogeneous cells of the immunosuppressive activity, including at different developmental stages of immature granulocytes, dendritic cells and macrophages, and so on. Myeloid derived suppressor cells can inhibit the innate immunity, adaptive immunity mediated by CD4+ and CD8+ T cells, and stimulate tumor growth and metastasis through mediated tumor immune escape. Proinflammatory cytokines are a group of endogenous polypeptides that are mainly produced by immune system cells and have powerful biological effects. They mediate a variety of immune responses. Although molecular mechanisms of MDSCs and proinflammatory cytokines in ovarian cancer are not quite clear, but the current study suggests that some proinflammatory cytokines can induce MDSCs amplification, thus promoting tumor growth and development. Targeted therapies are new treatments besides routine surgery and chemotherapy. MDSCs have potential as clinical targets for immunotherapy. This article reviews research on the occurrence, development and treatment of MDSCs in ovarian carcinoma in order to reveal the mechanism of action of MDSCs and the provide theoretical basis for new treatment methods.